Literature DB >> 16259580

Oseltamivir in the management of influenza.

John Oxford1.   

Abstract

Seasonal influenza causes significant morbidity and mortality in adults and children. However, a worldwide influenza pandemic could cause considerably more deaths (20-40 million) and would majorly disrupt everyday life in most countries. Oseltamivir has proven to be safe and effective for the prevention or treatment of all known influenza subtypes, reducing the severity and duration of symptoms, the complications arising from influenza infection (pneumonia, hospitalisation, antibiotic use) and mortality. Oseltamivir has been shown to be effective against pandemic strains of influenza, including the currently circulating strain (H5N1). As a result, the World Health Organization has recommended the stockpiling of oseltamivir in the event of an influenza pandemic.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16259580     DOI: 10.1517/14656566.6.14.2493

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  8 in total

1.  The 2008-2009 H1N1 influenza virus exhibits reduced susceptibility to antibody inhibition: Implications for the prevalence of oseltamivir resistant variant viruses.

Authors:  Wai Lan Wu; Siu-Ying Lau; Yixin Chen; Genyan Wang; Bobo Wing-Yee Mok; Xi Wen; Pui Wang; Wenjun Song; Tianwei Lin; Kwok-Hung Chan; Kwok-Yung Yuen; Honglin Chen
Journal:  Antiviral Res       Date:  2011-11-25       Impact factor: 5.970

2.  In vitro pharmacological selectivity profile of oseltamivir prodrug (Tamiflu) and active metabolite.

Authors:  Lothar Lindemann; Helmut Jacobsen; Diana Schuhbauer; Frederic Knoflach; Silvia Gatti; Joseph G Wettstein; Hansruedi Loetscher; Tom Chu; Martin Ebeling; James C Paulson; Eric Prinssen; Manfred Brockhaus
Journal:  Eur J Pharmacol       Date:  2009-11-14       Impact factor: 4.432

3.  Oseltamivir pharmacokinetics and clinical experience in neonates and infants during an outbreak of H1N1 influenza A virus infection in a neonatal intensive care unit.

Authors:  Joseph F Standing; Angela Nika; Vasileios Tsagris; Ioannis Kapetanakis; Helena C Maltezou; Dimitris A Kafetzis; Maria N Tsolia
Journal:  Antimicrob Agents Chemother       Date:  2012-05-07       Impact factor: 5.191

4.  Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system.

Authors:  Gerhard Hoffmann; Christoph Funk; Stephen Fowler; Michael B Otteneder; Alexander Breidenbach; Craig R Rayner; Tom Chu; Eric P Prinssen
Journal:  Antimicrob Agents Chemother       Date:  2009-08-31       Impact factor: 5.191

Review 5.  Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology.

Authors:  Charlotte I S Barker; Eva Germovsek; Rollo L Hoare; Jodi M Lestner; Joanna Lewis; Joseph F Standing
Journal:  Adv Drug Deliv Rev       Date:  2014-01-17       Impact factor: 15.470

Review 6.  Antivirals for the treatment and prevention of epidemic and pandemic influenza.

Authors:  John S Oxford
Journal:  Influenza Other Respir Viruses       Date:  2007-01       Impact factor: 4.380

Review 7.  [Emerging viral infectious diseases and pregnancy].

Authors:  P-F Ceccaldi; P Longuet; L Mandelbrot
Journal:  Gynecol Obstet Fertil       Date:  2007-03-26

Review 8.  Status presens of antiviral drugs and strategies: Part II: RNA VIRUSES (EXCEPT RETROVIRUSES).

Authors:  Erik De Clercq
Journal:  Adv Antivir Drug Des       Date:  2007-09-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.